JESSICA MUELLEMAN: Open Payments
NPI 1437912466 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 31 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 4 | $185 |
| Galderma Laboratories, L.P. | 2 | $155 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $57 |
| Amgen Inc. | 3 | $56 |
| MAYNE PHARMA COMMERCIAL LLC | 6 | $49 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| ABBVIE INC. | 2 | $36 |
| Genentech USA, Inc. | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
Products named: Bimzelx, NEMLUVIO, ILUMYA, OTEZLA, COSENTYX, DUPIXENT, SKYRIZI, Xolair.
Industry payments across MO — which companies pay providers there.
